



ASX release

21 July 2015

Rights Issue Update

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced the results of its 1 for 10 non-renounceable rights offer which opened on 6 July 2015.

AtCor received valid applications for \$1,335,543 comprising \$1,112,455 in entitlement acceptances and \$223,088 as applications for additional shares. This represents approximately 41% of available shares taken up. All valid applicants will receive their full entitlement and any additional shares applied for through the offer. This will result in 7,419,686 new shares being issued. As a fully underwritten offer, the shortfall of 10,373,707 shares will be issued to clients of the Underwriter, Taylor Collison Limited as per the terms of the underwriting agreement.

Total funds raised before costs and expenses are \$3,202,810.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,800 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 900 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au